The Olon Group, Biosphere and the Biocatalysis Group of the Van't Hoff Institute for Molecular Sciences (HIMS-Biocat) at the University of Amsterdam (UvA) announce the creation of an international network of scientific excellence, bringing together industrial and academic expertise in the field of biocatalysis and industrial biotechnology.

Biosphere is proud to be part of the Bizente project. The project, coordinated by the Aragon-based technology centre AITIIP, has received funding from the Bio Based Industries Joint Undertaking under the European Union’s Horizon 2020 research and innovation programme under grant agreement No 886567. Aim of the project is to resolve end-of-life issues of thermoset composite plastics by applying customised ligninases.

Biosphere's Chairman of the Board is among the representatives of 63 industry members of the Bio-based Industries Consortium who have signed an open letter addressed to the European Commission, in support of a stronger recognition of the bio-based sector in the EU's green recovery.

Biosphere will be attending the IFIB 2019 Conference and Brokerage Event in Naples on 3-4 October, 2019. Join us for a two-day insight in the world of Bioeconomy and Industrial Biotechnology.

We are happy to meet you at the ECP-event in Frankfurt later in February. It is our first participation and we are looking forward to a fruitful day of meetings and discussions on technologies and business opportunities.

Biosphere is present at the Bio-Europe Spring 2018 in Amsterdam.

From December 2017 Biosphere is a new Full Member of the Biobased Industries Consortium.

Biosphere will be attending the IFIB 2017 Conference and Partnering Event in Rome on 5-6 October 2017. Our COO is an invited speaker in the "Biobased Industries" session in the afternoon of October 5th.

The event mix with the world of Pharma products, people & solutions. Biosphere will be present as visitor, send us an email at info@biospheresrl.com , we can arrange a meeting!

Biosphere, specialized in biotech process development and customized enzymes production, join forces with ARTES Biotechnology, a technology provider focused on microbial cell line and process development for recombinant protein production.